MDT

95.74

-0.41%↓

VEEV

282.54

-1.59%↓

A

137.38

+0.39%↑

HQY

91.97

+1.39%↑

PHR.US

21.72

-1.32%↓

MDT

95.74

-0.41%↓

VEEV

282.54

-1.59%↓

A

137.38

+0.39%↑

HQY

91.97

+1.39%↑

PHR.US

21.72

-1.32%↓

MDT

95.74

-0.41%↓

VEEV

282.54

-1.59%↓

A

137.38

+0.39%↑

HQY

91.97

+1.39%↑

PHR.US

21.72

-1.32%↓

MDT

95.74

-0.41%↓

VEEV

282.54

-1.59%↓

A

137.38

+0.39%↑

HQY

91.97

+1.39%↑

PHR.US

21.72

-1.32%↓

MDT

95.74

-0.41%↓

VEEV

282.54

-1.59%↓

A

137.38

+0.39%↑

HQY

91.97

+1.39%↑

PHR.US

21.72

-1.32%↓

Search

Arcutis Biotherapeutics Inc

Abrir

SetorSaúde

20.15 -2.75

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.23

Máximo

21.02

Indicadores-chave

By Trading Economics

Rendimento

9.2M

-16M

Vendas

16M

82M

Margem de lucro

-19.491

Funcionários

342

EBITDA

6.7M

-12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+13.67% upside

Dividendos

By Dow Jones

Próximos Ganhos

28 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

639M

2.4B

Abertura anterior

22.9

Fecho anterior

20.15

Sentimento de Notícias

By Acuity

38%

62%

135 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de out. de 2025, 21:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 de out. de 2025, 21:07 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 de out. de 2025, 17:03 UTC

Grandes Movimentos do Mercado

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 de out. de 2025, 23:53 UTC

Conversa de Mercado

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 de out. de 2025, 23:39 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 de out. de 2025, 22:15 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de out. de 2025, 22:15 UTC

Conversa de Mercado

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 de out. de 2025, 21:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 de out. de 2025, 21:36 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de out. de 2025, 21:36 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

13 de out. de 2025, 21:36 UTC

Conversa de Mercado

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 de out. de 2025, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 de out. de 2025, 21:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 de out. de 2025, 20:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 de out. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

13 de out. de 2025, 20:35 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Expects to Close Deal in 1Q

13 de out. de 2025, 20:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 de out. de 2025, 20:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 de out. de 2025, 20:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 de out. de 2025, 20:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 de out. de 2025, 20:29 UTC

Aquisições, Fusões, Aquisições de Empresas

Goldman Sachs to Buy VC Firm Industry Ventures

13 de out. de 2025, 19:05 UTC

Conversa de Mercado

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 de out. de 2025, 18:59 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 de out. de 2025, 18:26 UTC

Conversa de Mercado

Precious Metals Close at New Record Highs -- Market Talk

13 de out. de 2025, 18:10 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de out. de 2025, 18:10 UTC

Conversa de Mercado

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 de out. de 2025, 17:05 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

13 de out. de 2025, 17:05 UTC

Conversa de Mercado

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 de out. de 2025, 16:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 de out. de 2025, 15:35 UTC

Conversa de Mercado

Precious Metals Push Record Highs Further -- Market Talk

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

13.67% parte superior

Previsão para 12 meses

Média 22.79 USD  13.67%

Máximo 29 USD

Mínimo 14.29 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

7

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

12.42 / 14.93Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

135 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat